[G25-21] Sipavibart (pre exposure prophylaxis of COVID 19) – 2nd Addendum to Project A25-28
Last updated 07.08.2025
Project no.:
G25-21
Commission:
Commission awarded on 24.06.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Immune system and infections
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
DOI:
https://doi.org/10.60584/G25-21
| Project no. | Title | Status |
|---|---|---|
| A25-28 | Sipavibart (pre-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
07-08-2025 A G-BA decision was published.
G-BA documents on this decision